The strong efficacy and manageable safety profile, combined with priority review, suggest a high likelihood of NMPA approval. Traders should monitor the NMPA decision timeline and any updates on global development plans. The ESMO GI presentation on July 4, 2026, may provide additional detail and investor attention.
HCM drugs
HCM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 26 $10.17entry
- T+1 · 5mo ago +5.31%α +3.66% · $10.71
- T+5 · 4mo ago +14.55%α +11.49% · $11.65
- T+20 · 4mo ago +9.34%α +7.96% · $11.12
- T+60 · 8w ago +38.35%α +32.26% · $14.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED announced positive pivotal Phase II results for fanregratinib in FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma (ICC), with an IRC-assessed ORR of 42.5% and median OS of 16.6 months. The NDA has been accepted and granted priority review by China's NMPA, positioning fanregratinib as a potential new treatment option in a targeted ICC population.
Key Facts
- Pivotal Phase II study met primary endpoint with IRC-assessed ORR of 42.5% (95% CI: 30.0%–53.6%) in advanced ICC patients with FGFR2 fusions/rearrangements.
- Median progression-free survival (PFS) was 6.9 months; median overall survival (OS) was 16.6 months.
- NDA for fanregratinib in this indication accepted and granted priority review by China's NMPA in December 2025.
- Drug-related Grade 3+ adverse events occurred in 48.3% of patients; treatment discontinuation due to AEs was only 2.2% with no treatment-related deaths.
- Fanregratinib is a novel, selective FGFR 1/2/3 inhibitor; HUTCHMED retains worldwide rights.
Financial Impact
Positive Phase II data and priority review status support potential approval in China, expanding HUTCHMED's oncology portfolio. Fanregratinib addresses a niche but high-unmet-need ICC population; peak sales potential not disclosed but could be material given orphan-like indication.
Risk Factors
- Competition from approved FGFR inhibitors (pemigatinib, infigratinib) in similar indications.
- Grade 3+ AE rate of 48.3% may raise safety concerns despite low discontinuation.
- Commercial success depends on pricing, reimbursement, and physician adoption in China.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3317235 |
Track record
33 reports on HCM
7 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.33% at T+60 after the Jul 30, 2026 report. 17 of 22 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers